

Small Cell Lung Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member ID: _____ Treatment Start Date: _____

Stage: _____ Pathology: _____

ECOG Status: 1 2 3 4 ICD-10 Code: _____

Line of Therapy:

- Neoadjuvant/Pre-op
 Adjuvant/Post Op
 1st Line
 2nd Line
 3rd Line
 3rd Line+
 Maintenance

Biomarkers/Attributes: (select all that apply)

Platinum Sensitive*: <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not Reported	Prior use of anti-PD-1 agents: <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not Reported
Platinum Resistant/Refractory*: <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not Reported	

* Platinum sensitive is defined as recurrence of greater than 6 months after prior platinum-based therapy and resistance is defined as a recurrent of less than 6 months after prior platinum-based therapy

Limited Stage – Adjuvant or Primary Therapy

- Carboplatin + Etoposide
- Cisplatin + Etoposide

Extensive Stage – Adjuvant or Primary Therapy

- Carboplatin + Etoposide + Atezolizumab
- Carboplatin + Etoposide + Durvalumab
- Cisplatin + Etoposide + Durvalumab
- Carboplatin + Etoposide
- Cisplatin + Etoposide

Extensive Stage – Adjuvant or Primary Therapy - Maintenance

- Atezolizumab
- Durvalumab

Subsequent Therapy: Relapse ≤ 6 months

- Topotecan IV / PO
- Lurbinectedin

Subsequent Therapy: Relapse > 6 months

- Carboplatin + Etoposide
- Cisplatin + Etoposide
- Topotecan IV / PO
- Lurbinectedin

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.



References:

Rudin CM, Ismaila N, Hann CL, et al. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. *J Clin Oncol*. 2015;33(34):4106-4111. doi:10.1200/JCO.2015.63.7918

Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl):e400S-e419S. doi:10.1378/chest.12-2363

Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. *Ann Oncol*. 2021;32(7):839-853. doi:10.1016/j.annonc.2021.03.207

National Comprehensive Cancer Network. Small Cell Lung Cancer (Version 2.2022)
https://www.nccn.org/professionals/physician_gls/pdf/sclc_blocks.pdf

National Comprehensive Cancer Network. Hematopoietic Growth Factors (Version1.2022)
https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf

Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [published correction appears in *Lancet Oncol*. 2016 Jul;17 (7):e270] [published correction appears in *Lancet Oncol*. 2019 Feb;20(2):e70]. *Lancet Oncol*. 2016;17(7):883-895. doi:10.1016/S1470-2045(16)30098-5

Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer [published correction appears in *J Clin Oncol*. 2007 Aug 1;25(22):3387.]. *J Clin Oncol*. 2007;25(15):2086-2092. doi:10.1200/JCO.2006.08.3998

Elegbede AA, Gibson AJ, Fung AS, et al. A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada. *JTO Clin Res Rep*. 2021;2(12):100249. Published 2021 Oct 28. doi:10.1016/j.jtocrr.2021.100249

Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. *J Clin Oncol*. 1985;3(11):1471-1477. doi:10.1200/JCO.1985.3.11.1471

Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Oncol*. 2017;18(8):1116-1125. doi:10.1016/S1470-2045(17)30318-2

Ferrarotto R, Anderson I, Medgyasszay B, et al. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. *Cancer Med*. 2021;10(17):5748-5756. doi:10.1002/cam4.4089

Furuse K, Kubota K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. *Oncology*. 1996;53(2):169-172. doi:10.1159/000227555

Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2021;22(1):51-65. doi:10.1016/S1470-2045(20)30539-8

Horn L, Mansfield AS, Szczesna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2018;379(23):2220-2229. doi:10.1056/NEJMoa1809064

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. *J Clin Oncol*. 1990;8(10):1613-1617. doi:10.1200/JCO.1990.8.10.1613

Karachiwala H, Tilley D, Abdel-Rahman O, Morris D. Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study. *Clin Respir J*. 2021;15(1):36-41. doi:10.1111/crj.13266

Lammers PE, Shyr Y, Li CI, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. *J Thorac Oncol*. 2014;9(4):559-562. doi:10.1097/JTO.000000000000079

Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). *J Clin Oncol*. 2021;39(6):619-630. doi:10.1200/JCO.20.01055

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol*. 2020;38(1):1-10. doi:10.1200/JCO.19.02105

Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. *J Clin Oncol*. 2003;21(8):1550-1555. doi:10.1200/JCO.2003.09.130

Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. *J Clin Oncol*. 1992;10(8):1225-1229. doi:10.1200/JCO.1992.10.8.1225

Niell HB, Herndon JE 2nd, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. *J Clin Oncol*. 2005;23(16):3752-3759. doi:10.1200/JCO.2005.09.071

Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Engl J Med*. 2002;346(2):85-91. doi:10.1056/NEJMoa003034

O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. *J Clin Oncol*. 2006;24(34):5441-5447. doi:10.1200/JCO.2006.06.5821

Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. *J Clin Oncol*. 1999;17(11):3540-3545. doi:10.1200/JCO.1999.17.11.3540

Ott PA, Elez E, Hirt S, et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. *J Clin Oncol*. 2017;35(34):3823-3829. doi:10.1200/JCO.2017.72.5069

Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-6

Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. *Clin Cancer Res*. 2012;18(4):1138-1145. doi:10.1158/1078-0432.CCR-11-2059

Ready NE, Ott PA, Hellmann MD, et al. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. *J Thorac Oncol*. 2020;15(3):426-435. doi:10.1016/j.jtho.2019.10.004

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. *J Clin Oncol*. 2012;30(14):1692-1698. doi:10.1200/JCO.2011.40.4905

Schmittel A, Fischer von Weikersthal L, Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. *Ann Oncol*. 2006;17(4):663-667. doi:10.1093/annonc/mdj137

Schmittel A, Sebastian M, Fischer von Weikersthal L, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. *Ann Oncol*. 2011;22(8):1798-1804. doi:10.1093/annonc/mdq652

Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. *Eur J Cancer*. 1994;30A(8):1058-1060. doi:10.1016/0959-8049(94)90455-3

Subbiah V, Paz-Ares L, Besse B, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. *Lung Cancer*. 2020;150:90-96. doi:10.1016/j.lungcan.2020.10.003

Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial [published correction appears in *Lancet Oncol*. 2020 Dec;21(12):e553]. *Lancet Oncol*. 2020;21(5):645-654. doi:10.1016/S1470-2045(20)30068-1

Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med*. 1999;340(4):265-271. doi:10.1056/NEJM199901283400403

van der Lee I, Smit EF, van Putten JW, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. *Ann Oncol*. 2001;12(4):557-561. doi:10.1023/a:1011104509759

von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol*. 1999;17(2):658-667. doi:10.1200/JCO.1999.17.2.658

Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. *Anticancer Res*. 2006;26(1B):777-781.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.